Quality of life in purely ocular myasthenia in Japan by Shigeaki Suzuki et al.
Suzuki et al. BMC Neurology 2014, 14:142
http://www.biomedcentral.com/1471-2377/14/142RESEARCH ARTICLE Open AccessQuality of life in purely ocular myasthenia in
Japan
Shigeaki Suzuki1*, Hiroyuki Murai2, Tomihiro Imai3, Yuriko Nagane4, Masayuki Masuda5, Emiko Tsuda3,
Shingo Konno6, Satoru Oji7, Shunya Nakane8, Masakatsu Motomura9, Norihiro Suzuki1 and Kimiaki Utsugisawa4Abstract
Background: Since there has been no conclusive evidence regarding the treatment of ocular myasthenia,
treatment guidelines were recently issued by the European Federation of Neurological Societies/European
Neurological Society (EFNS/ENS). However, the therapeutic outcomes concerning the quality-of-life (QOL) of patients
with ocular myasthenia are not yet fully understood.
Methods: We investigated the therapeutic outcomes of patients with purely ocular myasthenia in a multicenter
cross-sectional survey in Japan. To evaluate the severity of ocular symptoms, we used the ocular-quantitative MG
(QMG) score advocated by Myasthenia Gravis Foundation of America. We used the Japanese translated version of
the MG-QOL15, a self-appraised scoring system.
Results: Of 607 myasthenia gravis (MG) patients with an observation-duration of illness≥ 2 years, the cases of 123
patients (20%) were limited to ocular muscles (purely ocular myasthenia). During the entire clinical course, 81 patients
experienced both ptosis and diplopia, 36 had ptosis alone, and six had diplopia alone. Acetyl-cholinesterase inhibitors
and prednisolone were used in 98 and 52 patients, respectively. Treatment improved ocular symptoms, with the mean
reduction in ocular-QMG score of 2.3 ± 1.8 points. However, 47 patients (38%) failed to gain minimal manifestation or a
better status. Patients with unfavorable outcomes also self-reported severe QOL impairment. Multivariate analyses
showed that the pretreatment ocular-QMG score was associated with unfavorable outcomes, but not associated with
the patient’s QOL.
Conclusion: A treatment strategy designed in accord with a patient's ocular presentation must be considered in order
to improve ocular symptoms and the patient's QOL.
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Ocular myasthenia is a form of myasthenia gravis (MG)
that is clinically restricted to extrinsic ocular muscles
[1,2]. Clinical signs of ocular myasthenia can be highly
variable, ranging from mild unilateral ptosis to complete
opthalmoplegia. Ptosis and diplopia may be present,
involving various combinations of the levator palpebrae,
the two obliques, and the four recti muscles. It is thought
that these extraocular muscles have less prominent
synaptic folds and/or lower expressions of complement
regulators, which makes these muscles vulnerable to* Correspondence: sgsuzuki@z3.keio.jp
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unless otherwise stated.autoimmune attacks [1,3]. Almost one-half of MG
patients present with ocular symptoms, and 50%–60%
progress to the generalized disease, mostly within the first
2 years [4,5]. The percentage of patients with MG who
suffer from purely ocular symptoms during the entire
course has been reported to be 12%–20% of the whole
MG population [1,2,4,5].
Several studies reported that corticosteroid was effective
for preventing the progression from ocular myasthenia to
generalized MG [6-11]. However, a systematic review
concluded that there was no clear evidence supporting
corticosteroid use for ocular myasthenia [12]. In addition
to generalization from ocular myasthenia, the treatment
of ocular symptoms in purely ocular myasthenia has
varied, since neurologists had to select treatment regimensLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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In this context, the European Federation of Neurological
Societies/European Neurological Society (EFNS/ENS)
guidelines for the treatment of ocular myasthenia were
recently published [13]. To the best of our knowledge,
there are no reports of therapeutic outcomes that include
the patients’ quality-of-life (QOL) in a large number of
patients with purely ocular myasthenia.
The purpose of the present study was to investigate
the therapeutic outcomes of purely ocular myasthenia,
including QOL measures, in a cross-sectional survey
from numerous centers in Japan.
Methods
Eleven neurological centers participated in the present
study as the Japan MG Registry Group. We evaluated
patients with established MG who attended these centers
between April and July 2012. To avoid potential bias, we
enrolled consecutive patients with various stages of illness
over a short duration in this multicenter cross-sectional
study. All clinical information was collected after the
patients gave their written informed consent. All study
protocols were approved by the ethics committee of Keio
University Hospital, the ethics committee of Hanamaki
General Hospital, the ethics committee of Iizuka Hospital,
the ethics committee of Sapporo Medical University
Hospital, the ethics committee of Saitama Medical Center,
the ethics committee of Tokyo Medical University
Hospital, the ethics committee of Toho University
Medical Center Ohhashi Hospital, the ethics committee of
Sendai Medical Center, the ethics committee of Tohoku
University Hospital, the ethics committee of Nagasaki
University Hospital, and the ethics committee of Nagasaki
Kawatana Medical Center.
The diagnosis of MG was based on clinical findings
(fluctuating symptoms with easy fatigability and recovery
after rest) with amelioration of symptoms after an
intravenous administration of acetyl-cholinesterase
(AChE) inhibitors, decremental muscle response to a
train of low-frequency repetitive nerve stimuli, or the
presence of antibodies against skeletal muscle acetylcholine
receptor (AChR) [1]. We excluded other disorders which
caused ptosis and/or diplopia using various examinations,
especially in anti-AChR negative patients. At some of the
participating institutions, single-fiber electromyography
was used to detect jitter phenomena in the orbicularis
oculi muscles.
Clinical information was retrospectively obtained by
reviewing the patients’ clinical charts. The patients’
clinical features were evaluated according to the Task
Force of the Medical Advisory Board of the Myasthenia
Gravis Foundation of America (MGFA) [14]. To evaluate
the severity of ocular symptoms, we used the MGFA
ocular-quantitative MG (QMG) score, which includeslevator function, extraocular muscle function, and the
strength of orbicularis oculi among the 13 items of the
QMG score [15]. Disease subtypes were classified into
early-onset, late-onset, and thymoma-associated MG [16].
Therapeutic outcomes were assessed by the MGFA
post-interventional status and the patients’ QOL. We
used the Japanese translated version of the MG-QOL15
(MG-QOL15-J) [17], a self-appraised scoring system. It
was simple, easy to administer, user-friendly, and quick to
assess the impact of a disease.
The spectrum of treatment included AChE inhibitors,
corticosteroids, other immunosuppressants, high-dose
intravenous methylpredonisolone pulse therapy (mPSL),
high doses of immunoglobulin (IVIg), plasmapheresis
and extended thymectomy. Among the AChE inhibitors
drugs, pyridostigmine bromide (Mestinon®) was usually
used. Among oral corticosteroids, prednisolone (PSL)
was generally used. The purpose of an additional use of
immunosuppressants was to taper the dose of PSL and to
reduce the side effects of PSL. Since the use of tacrolimus
and cyclosporine was approved by the Japanese Ministry
of Welfare in 2000 and 2006, other immunosuppressants
including azathioprine and mycophenolate are principally
not used in Japan. Plasmapheresis was performed for
immunoadsorption using a tryptophan column (TR-350,
Asahi Medical, Tokyo). The therapeutic decisions of
ocular myasthenia had not been made based on the
confirmed protocol, however, the principal treatment
methods were similar in all participating institutions
in accordance with the guidelines [13].
Comparisons between the favorable and unfavorable
outcomes were made using the chi-square test or the
Mann–Whitney U-test when appropriate. A multivariate
analysis was performed using the Cox proportional
hazards regression model to determine independent
factors associated with unfavorable outcomes. The
statistical analyses were performed using IBM/SPSS
software (version 20; Armonk, NY).
Results
For the investigation of the clinical features of purely ocu-
lar myasthenia, MG patients with an observation-duration
of illness ≥ 2 years were enrolled. Of 607 MG patients,
123 (20%) patients who showed the worst condition
(graded MGFA class 1) were regarded as having
purely ocular myasthenia. Their mean age was age
60.9 ± 15.8 years, and the male/female ratio was 54:69.
The observational period was 7.8 ± 6.0 years. Forty-one
patients had early-onset MG, 68 patients had late-onset
MG, and the cases of 14 patients were thymoma-associated.
During the entire clinical course, 81 patients (66%)
experienced both ptosis and diplopia, 36 (29%) had
ptosis alone, and six (5%) had diplopia alone. Although
anti-AChR antibodies were detected in 92 patients,
Figure 1 Distribution of pre- and post-treatment ocular-quantitative
myasthenia gravis (QMG) scores of the 123 patients with purely
ocular myasthenia.
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antibodies.
The patients’ treatments included AChE inhibitors
in 98 patients (80%), oral PSL in 52 (42%), other
immunosuppressants in 28 (23%), mPSL in 23 (19%),
plasmapheresis in 6 (5%), IVIg in 1 (1%), and thymectomy
in 31 (25%). The current dose of pyridostigmine was
101.0 ± 66.7 mg/day. The maximum dose of PSL was
20.4 ± 13.0 mg/day.
Figure 1 shows the distribution of pre- and post-treatment
ocular-QMG scores in all 123 patients with purely
ocular myasthenia. The mean reduction in ocular-QMG
score was 2.3 ± 1.8 points, and the reductions ranged
from 4.0 ± 1.8 points to 1.7 ± 2.0 points. The MGFA
post-interventional status was ‘complete stable remission’
in 16 patients (13%), ‘pharmacological remission’ in six
(5%), ‘minimal manifestation (MM)’ in 54 (44%), ‘improved’
in 23 (19%), and ‘unchanged’ in 24 (20%). We considered
MM or better status (i.e., pharmacological remission or
complete stable remission) as a practical treatment
goal [17]. Seventy-six (62%) of all patients with ocular
myasthenia achieved MM or better status (i.e., a favorable
outcome). In contrast, 47 (38%) patients failed to gain
MM or better status (i.e., an unfavorable outcome).
We divided the 123 patients with purely ocular myas-
thenia into two groups: 76 patients with the favorable
outcome and 47 patients with the unfavorable outcome.
The demographic and clinical features of the two groups
are given in Table 1. There were no significant between
group differences in gender, age, observational period,
ocular symptoms, disease subtype, or seropositivity of
anti-AChR antibodies. In addition, there were no
significant differences in the treatment profiles between
the two groups. The current dose of pyridostigmine
was significantly higher in the patients with unfavor-
able outcomes than those with favorable outcomes
(132.0 ± 54.0 mg vs. 79.7 ± 66.6 mg, p < 0.0001).
The pretreatment ocular-QMG scores were significantly
higher in the patients with unfavorable outcomes compared
to those with favorable outcomes (4.5 ± 1.7 vs. 3.4 ± 1.7
points, p = 0.006). We conducted logistic analyses to
identify the clinical factors associated with the unfavorable
outcome. We examined the association between the
unfavorable outcome and the clinical factors of gender, age,
observational period, ocular symptoms, disease subtype,
seropositivity of anti-AChR antibodies, and treatment
profiles. The multivariate logistic regression analyses
revealed that the pretreatment ocular-QMG score was
the only factor associated with the unfavorable outcome
(odds ratio = 1.382, 95% confidence interval, 1.084–1.761,
p = 0.009).
Lastly, we evaluated the self-perceived QOL of patients
with purely ocular myasthenia by the MG-QOL15-J.
Forty-seven patients with an unfavorable outcome showedsignificantly higher scores on the total MG-QOL15-J
(more severely impaired QOL) compared to the 87
patients with the favorable outcome (15.7 ± 12.7 vs.
5.7 ± 8.5 points, p < 0.0001). The comparison of the 15
items of the MG-QOL-15 is shown in Figure 2. Patients
with the unfavorable outcome scored themselves as
"severe" for 11 of 15 items of the QOL survey, more than
those with the favorable outcome. Although we also
examined the association between the QOL and the
Table 1 The favorable and unfavorable outcome groups





(n = 76) (n = 47) p-value
Female 42 (55%) 27 (57%) 0.81
Age, yr 61.1 ± 16.1 60.4 ± 15.4 0.81
Observational period, yr 7.2 ± 4.6 8.7 ± 7.7 0.22
Subtype
Early-onset 23 (30%) 18 (38%) 0.33
Late-onset 42 (55%) 26 (55%) 1.00
Thymoma-associated 11 (14%) 3 (6%) 0.17
Symptoms
Ptosis and diplopia 49 (64%) 32 (68%) 0.68
Ptosis alone 22 (29%) 14 (30%) 0.92
Diplopia alone 5 (7%) 1 (2%) 0.26
Anti-acetylcholine receptor positive 60 (79%) 32 (68%) 0.18
Treatment
Acetyl-cholinesterase inhibitors 58 (86%) 41 (78%) 0.14
Pyridostigmine (mg/day) 79.7 ± 66.6 132.0 ± 54.0 <0.0001
Oral prednisolone 27 (36%) 25 (53%) 0.053
Maximum dose (mg/day) 19.4 ± 10.4 21.5 ± 15.5 0.58
Immunosuppressants 14 (18%) 14 (30%) 0.14
mPSL 11 (14%) 12 (26%) 0.13
Plasmapheresis 2 (3%) 4 (9%) 0.14
Immunoglobulin 1 (1%) 0 (0%) 0.43
Thymectomy 20 (26%) 11 (23%) 0.71
Ocular-QMG score
Pre-treatment 3.4 ± 1.7 4.5 ± 1.7 0.006
Post-treatment 0.6 ± 0.8 3.4 ± 2.1 <0.0001
MG-QOL15-J score 5.7 ± 8.5 15.7 ± 12.7 <0.0001
mPSL, intravenous methylpredonisolone pulse therapy.
QMG, quantitative MG score; MGFA, Myasthenia Gravis Foundation of America.
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profiles using the multivariate logistic analyses, we
could not find the significant factor associated the
self-perceived QOL.
Discussion
The present multicenter cross-sectional survey in Japan
was comprised of the treatment profiles and therapeutic
outcomes of 123 patients with purely ocular myasthenia.
To investigate the clinical features of purely ocular
myasthenia, we enrolled MG patients with durations of
symptoms ≥2 years. The main results can be summarized
as follows: (i) the frequency of purely ocular myasthenia
was 20% in all MG patients; (ii) treatment improved
the ocular symptoms with the mean reduction in
ocular-QMG score of 2.3 ± 1.8 points; (iii) 38% of thepatients failed to gain MM or a better status; (iv) the
unfavorable outcome was also demonstrated by severe
QOL impairment; and (v) the multivariate analyses
showed that the pretreatment ocular-QMG score was
associated with unfavorable outcomes, but not associated
with patient’s QOL.
The present study has two limitations. First, the
cross-sectional study did not allow us to draw any
conclusions about the treatment selection of ocular
myasthenia. Second, we obtained no data regarding the
association between drug therapy and generalization from
ocular myasthenia. An evidence-based review made no
conclusion regarding whether it was appropriate to initiate
therapy with AChE inhibitors or with corticosteroids
for patients with ocular myasthenia [12]. However, the
EFNS/ENS guidelines recommend that the treatment of
ocular myasthenia should initially be started with pyrido-
stigmine [13]. We agree with the principal concept of the
EFNS/ENS guidelines’ recommendation and initially treated
by AChE inhibitors in most patients with ocular myasthe-
nia. However, we should recognize that AChE inhibitors
alone usually will not solve the ocular myasthenia. We
emphasize that the indication for immunosuppressive treat-
ment should be carefully considered based on the severity
of ocular symptoms in order to improve the patient’s QOL.
The ocular symptoms can impair an individual’s vision
enough to interfere with work and daily life, but the
QOL of patients with purely ocular myasthenia had
not been elucidated prior to the present study. The
MG-QOL15-J, useful for identifying satisfaction or
dissatisfaction with the manifestations of MG among
patients receiving treatment, can capture various aspects
of QOL impairment [17]. We found a tight association
between the therapeutic outcome and QOL impairment
in purely ocular myasthenia. The MG-QOL15-J demon-
strated a marked gap (a total of 10 points) between the
favorable and unfavorable outcomes. It is likely that the
difference may be much greater than physicians’ global
impressions.
Apart from the generalization from ocular myasthenia,
we must consider the therapeutic strategy for purely
ocular myasthenia patients with the unfavorable outcome.
The treatment should minimize ocular symptoms with
minimal side effects and must be tailored to the individual,
based on his or her particular ocular symptoms [12,13,18].
In patients with severe opthalmoplegia, therapy with
AChE inhibitors alone may result in irreversible eye
movement. We think that immunotherapy can be
started when an ocular myasthenia patient has a high
ocular-QMG score. In fact, 42% of our patients received
PSL with the maximum dose of 20.4 mg/day. Since cortico-
steroid treatment did not result in the satisfactory control
of ocular symptoms, we used steroid-sparing treatment
with tacrolimus or cyclosporine in 28% of all patients.
Figure 2 Scores on the 15 items of MG-QOL15-J. Statistical analyses were performed between the unfavorable (n = 47) and favorable
(n = 76) outcome groups. †p < 0.05, #p < 0.01, and *p < 0.001.
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pheresis were performed in some patients. However, we
also think that these treatments are not indicated for
purely ocular myasthenia [13]. In contrast, we consider
that mPSL is a potentially effective treatment for ocular
myasthenia. It was reported that repeated mPSL in
addition to oral PSL was effective for ocular symptoms
without initial worsening [19]. In fact, our present find-
ings revealed that mPSL was administered in 19% of all
of the patients with purely ocular myasthenia, and 91%
of them experienced effective responses. Thus, we think
mPSL is the good choice of patients with the unfavor-
able condition and effective for improving the patient’s
QOL. Extended thymectomy was performed in 17 non-
thymomatous patients, only when drug therapy had
failed. Among the 14 patients with thymoma-associated
ocular MG, 11 had a favorable outcome. However, there
was no definite data regarding whether thymectomy was
contributed to the favorable outcome.
We believe that the treatment of sole ptosis may ne-
cessitate a particular approach. We found that theproportion of patients with ptosis alone during the en-
tire course among all of the MG patients was 6% (36/
607). It is likely that corticosteroids are less effective for
ptosis than for generalized symptoms of MG [18]. Ptosis
can be corrected by the placement of “crutches” in the
patient’s spectacles, and ptosis tape elevates the eyelid
droop [18]. We also use topical naphazoline for treating
myasthenic ptosis. Naphazoline, a primary α2-agonist,
selectively increases the tone of Muller muscles without
mydriasis and successfully reduces myasthenic ptosis
[20]. Although rapid effects of topical naphazoline
without significant adverse effects were observed in 70%
of the MG patients in a previous study, their responses
were variable and temporary [20]. In cases of long-
standing and irreversible ptosis, surgery for ptosis may be
considered [21].
Conclusion
A treatment strategy designed in accord with a patient's
ocular presentation must be considered to improve the
ocular symptoms and the patient's QOL.
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